APMIS. 2025 Dec;133(12):e70100. doi: 10.1111/apm.70100.
ABSTRACT
Dysbiosis, an imbalance in the gut microbiota, has emerged as a critical factor in the development of various metabolic diseases, including dyslipidemia. Dyslipidemia, a multifactorial disorder influenced by both genetic and environmental factors, is a significant risk factor for cardiovascular diseases (CVD), such as coronary artery disease (CAD) and stroke. The gut microbiota plays a pivotal role in maintaining lipid homeostasis, interacting with the host's immune, metabolic, and endocrine systems. Recent studies have highlighted the involvement of microbiota-derived metabolites, such as bile acids, lipopolysaccharides, and short-chain fatty acids (SCFAs), in modulating lipid levels and regulating hyperlipidemia. Understanding these complex microbiome-host interactions opens new avenues for therapeutic interventions aimed at correcting lipid imbalances and restoring microbial balance. Approaches such as probiotics, prebiotics, synbiotics, and dietary modifications hold promise in managing dyslipidemia and preventing associated cardiovascular diseases. As research continues to unravel these connections, the microbiome is increasingly recognized as a promising target for therapeutic strategies in dyslipidemia.
PMID:41321251 | DOI:10.1111/apm.70100